Intas develops COVID-19 Hyperimmune Globulin, gets human trial approval

Intas Pharma Gets CDSCO Panel Nod To Study Human Normal ImmunoglobulinПодробнее

Epidemic Ethics: Is it OK for research participants to volunteer to be infected?Подробнее

COVID-19 HYPERIMMUNE GLOBULINS AND ANTIBODIES BY NIK NIKAM MDПодробнее

Scientists look at immune response to COVID-19 for answersПодробнее

How a Covid-19 Vaccine Human Trial WorksПодробнее

Model Informed Drug Development Approaches for Immunogenicity Assessments WorkshopПодробнее

KAMADA Coronavirus Immune-Globulin Q&A (English subs)Подробнее

Ultra-fast development of an anti-COVID-19 antibodyПодробнее

Development of Next-Generation Prophylactic Antibodies for COVID-19Подробнее

Forecast of Global Hyperimmune Globulins Consumption Market 2023Подробнее

Innovation in the Treatment of Drug-resistant Tuberculosis: The endTB Clinical TrialПодробнее

Intas Proudly Introduces Thymotas - a novel, patented research formulationПодробнее

2022 International Day of Immunology - Science, State and Challenges of COVID-19 vaccinesПодробнее

New COVID-19 Protein Vaccine | UW MedicineПодробнее

Breden, Neller, Corrie: Antibody and T-cell Receptor Sequences Promote Rapid Response to COVID-19Подробнее

The Future of mRNA with Nobel Laureate Drew Weissman, MD, PhDПодробнее

EMBL scientists exploring synthetic antibodies to stop coronavirusПодробнее

Dr. Laura Walker: Generation of Broad and Potent Neutralizing Antibodies to Speed Pandemic ResponsesПодробнее

Optimizing Access to Monoclonal Antibodies for COVID-19: US PerspectiveПодробнее